Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens

View Full Paper
Ask AI
Bookmark
Share

Authors

SJSarasa M.A. Johnson

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis reveals elranatamab improves progression-free survival over real-world regimens in multiple myeloma.

Key Points

  • To compare the efficacy of elranatamab and predominant treatment regimens in China for patients with relapsed/refractory multiple myeloma.
  • Retrospective cohort design comparing MM-3 trial data with COTA database
  • Evaluation of progression-free survival, duration of response, and overall survival
  • Utilized Cox proportional hazard models and inverse probability treatment weighting for analysis.
  • Elranatamab associated with longer PFS of 17.25 months versus 3.78 months for CSPCT1
  • Notable DOR improvement with elranatamab, median not reached compared to 4.63 months
  • Overall survival was numerically better with elranatamab, 17.58 months compared to 15.38 months for CSPCT1.

Cite This Study

Sarasa M.A. Johnson (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d016https://doi.org/10.1182/blood-2025-8128
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis2025
  2. 2Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial2025 · 7 citations
  3. 3Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-32025
  4. 4Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study2025
  5. 5Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial2025